Claims for Patent: 9,463,179

Summary for Patent: 9,463,179

Title:	Short acting phenylalkylamine calcium channel blockers and uses thereof
Abstract:	The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
Inventor(s):	Martin P. Maguire, Elise Rioux, Harry J. Leighton
Assignee:	Milestone Pharmaceuticals Inc
Application Number:	US14/949,107
Patent Claims:	1. A method of treating an ischemic heart condition or cardiac arrhythmia, comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula or a pharmaceutically acceptable addition salt thereof, or any enantiomer or diastereomer thereof, wherein each a, b, c, d, e, and f is, independently, —CH2—, —O—, —S—, or a single bond; each R11, R12, R13, R14, R15, R16, and R17 is, independently: H, lower alkyl, lower alkyl substituted with —CO2(lower alkyl), lower alkyl substituted with —CO2(lower alkoxyalkyl), lower alkyl substituted with fluorine or chlorine, lower alkoxyalkyl, lower alkoxyalkyl substituted with —CO2(lower alkyl), lower alkoxyalkyl substituted with —CO2(lower alkoxyalkyl), lower alkoxyalkyl substituted with fluorine or chlorine, or CO2R10; each R10 is, independently, lower alkyl or lower alkoxyalkyl; R18 is H or CN; and R19 is H, g is a single bond, and R20 is H, wherein at least one of R11, R12, R13, R14, R15, R16, and R17 is CO2R10, lower alkyl substituted by —CO2(lower alkyl), lower alkyl substituted with —CO2(lower alkoxyalkyl), lower alkoxyalkyl substituted with —CO2(lower alkyl), or lower alkoxyalkyl substituted with —CO2(lower alkoxyalkyl). 2. The method of claim 1, wherein said ischemic heart condition is selected from the group consisting of stable angina, unstable angina and vasospastic angina. 3. The method of claim 1, wherein said cardiac arrhythmia is selected from the group consisting of atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia (PSVT), premature atrial, nodal, or ventricular depolarizations, atrial tachycardia, ventricular tachycardia, ventricular fibrillation, and Torsades de Pointes. 4. A method of treating an ischemic heart condition or cardiac arrhythmia, comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of: or a pharmaceutically acceptable addition salt thereof. 5. The method of claim 4, wherein said ischemic heart condition is selected from the group consisting of stable angina, unstable angina, and vasospastic angina. 6. The method of claim 4, wherein said cardiac arrhythmia is selected from the group consisting of atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia (PSVT), premature atrial, nodal, or ventricular depolarizations, atrial tachycardia, ventricular tachycardia, ventricular fibrillation, and Torsades de Pointes. 7. The method of claim 4, wherein said compound is selected from the group consisting of: or a pharmaceutically acceptable addition salt thereof. 8. The method of claim 7, wherein said ischemic heart condition is selected from the group consisting of stable angina, unstable angina, and vasospastic angina. 9. The method of claim 7, wherein said cardiac arrhythmia is selected from the group consisting of atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia (PSVT), premature atrial, nodal, or ventricular depolarizations, atrial tachycardia, ventricular tachycardia, ventricular fibrillation, and Torsades de Pointes. 10. The method of claim 7, wherein said compound is or a pharmaceutically acceptable addition salt thereof. 11. The method of claim 10, wherein said ischemic heart condition is selected from the group consisting of stable angina, unstable angina, and vasospastic angina. 12. The method of claim 10, wherein said cardiac arrhythmia is selected from the group consisting of atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia (PSVT), premature atrial, nodal, or ventricular depolarizations, atrial tachycardia, ventricular tachycardia, ventricular fibrillation, and Torsades de Pointes.